Bullfrog AI (BFRG) Competitors $2.11 +0.09 (+4.46%) (As of 12:35 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends BFRG vs. VTGN, MGX, BCAB, CTMX, ALXO, LPTX, IMRX, ALGS, BYSI, and SPROShould you be buying Bullfrog AI stock or one of its competitors? The main competitors of Bullfrog AI include Vistagen Therapeutics (VTGN), Metagenomi (MGX), BioAtla (BCAB), CytomX Therapeutics (CTMX), ALX Oncology (ALXO), Leap Therapeutics (LPTX), Immuneering (IMRX), Aligos Therapeutics (ALGS), BeyondSpring (BYSI), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Bullfrog AI vs. Vistagen Therapeutics Metagenomi BioAtla CytomX Therapeutics ALX Oncology Leap Therapeutics Immuneering Aligos Therapeutics BeyondSpring Spero Therapeutics Vistagen Therapeutics (NASDAQ:VTGN) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment. Which has preferable valuation and earnings, VTGN or BFRG? Bullfrog AI has lower revenue, but higher earnings than Vistagen Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistagen Therapeutics$1.06M67.76-$29.36M-$1.24-2.08Bullfrog AI$60K306.30-$5.36M-$0.85-2.48 Does the MarketBeat Community favor VTGN or BFRG? Vistagen Therapeutics received 282 more outperform votes than Bullfrog AI when rated by MarketBeat users. CompanyUnderperformOutperformVistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Bullfrog AIN/AN/A Does the media refer more to VTGN or BFRG? In the previous week, Vistagen Therapeutics had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 1 mentions for Vistagen Therapeutics and 0 mentions for Bullfrog AI. Vistagen Therapeutics' average media sentiment score of 1.75 beat Bullfrog AI's score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Vistagen Therapeutics Very Positive Bullfrog AI Neutral Do institutionals and insiders believe in VTGN or BFRG? 78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 1.3% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 33.9% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is VTGN or BFRG more profitable? Bullfrog AI has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Vistagen Therapeutics-4,521.71% -36.35% -33.62% Bullfrog AI N/A -141.39%-124.63% Do analysts prefer VTGN or BFRG? Vistagen Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 481.40%. Given Vistagen Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Vistagen Therapeutics is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, VTGN or BFRG? Vistagen Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. SummaryVistagen Therapeutics beats Bullfrog AI on 13 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Bullfrog AI News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRG vs. The Competition Export to ExcelMetricBullfrog AIPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.38M$6.50B$5.09B$8.81BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-2.485.4594.6014.18Price / Sales306.30373.721,217.5288.10Price / CashN/A52.5939.4936.27Price / Book4.8010.266.956.35Net Income-$5.36M$153.22M$118.83M$225.71M7 Day Performance-7.05%-1.74%-1.52%-0.32%1 Month Performance-12.08%-7.22%-3.39%1.76%1 Year Performance-30.13%31.69%32.17%27.70% Bullfrog AI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRGBullfrog AIN/A$2.11+4.5%N/A-36.3%$18.38M$60,000.00-2.484Gap UpVTGNVistagen Therapeutics3.7849 of 5 stars$2.58-1.1%$15.00+481.4%-25.4%$71.83M$1.06M0.0040Positive NewsMGXMetagenomi3.1759 of 5 stars$1.85+12.1%$15.50+737.8%N/A$69.23M$44.76M0.00236Analyst ForecastHigh Trading VolumeBCABBioAtla2.8165 of 5 stars$1.43-3.6%$6.00+320.3%-11.4%$69.02M$250,000.000.0060Short Interest ↓Gap DownCTMXCytomX Therapeutics4.3829 of 5 stars$0.85-1.9%$5.77+576.1%-37.4%$66.82M$101.21M5.12170Short Interest ↓ALXOALX Oncology3.3432 of 5 stars$1.27+4.5%$12.50+888.1%-87.7%$66.72MN/A0.0040LPTXLeap Therapeutics2.4038 of 5 stars$2.60+0.4%$7.50+188.5%+25.1%$66.56M$1.50M0.0040Positive NewsIMRXImmuneering2.8292 of 5 stars$2.12+3.9%$12.80+503.8%-63.4%$65.83M$320,000.00-1.1160Analyst ForecastALGSAligos Therapeutics4.1561 of 5 stars$18.08-0.7%$75.00+314.8%+5.5%$64.91M$15.53M-1.3790High Trading VolumeBYSIBeyondSpringN/A$1.66-2.8%N/A+86.1%$64.88M$1.75M0.0080SPROSpero Therapeutics4.5944 of 5 stars$1.18-1.7%$5.00+323.7%-2.4%$64.33M$103.78M17.1546Analyst Forecast Related Companies and Tools Related Companies Vistagen Therapeutics Competitors Metagenomi Competitors BioAtla Competitors CytomX Therapeutics Competitors ALX Oncology Competitors Leap Therapeutics Competitors Immuneering Competitors Aligos Therapeutics Competitors BeyondSpring Competitors Spero Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BFRG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bullfrog AI Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bullfrog AI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
